

Gibson Dunn Advised X4 Pharmaceuticals on Closing of Public Offering and Full Exercise of Underwriters' Option to Purchase Additional Shares

Firm News | October 28, 2025

Gibson Dunn advised X4 Pharmaceuticals on its public offering of common stock and full exercise of the underwriters' option to purchase additional shares for gross proceeds of \$155.3 million.

Our corporate team was led by partners Ryan Murr, Branden Berns, and Melanie Neary and included associates Candice Johnson, Jasmine Vitug, and Anika Gidwani.

Related People

[Ryan A. Murr](#)

[Branden C. Berns](#)

[Melanie E. Neary](#)

[Candice D. Johnson](#)

[Jasmine L. Vitug](#)

[Anika Gidwani](#)

Related Capabilities

[Life Sciences](#)